Page last updated: 2024-09-04

tariquidar and docetaxel anhydrous

tariquidar has been researched along with docetaxel anhydrous in 2 studies

Compound Research Comparison

Studies (tariquidar)	Trials (tariquidar)	Recent Studies (post-2010) (tariquidar)	Studies (docetaxel anhydrous)	Trials (docetaxel anhydrous)	Recent Studies (post-2010) (docetaxel anhydrous)
210	16	138	12,110	3,216	6,920

Protein Interaction Comparison

Protein	Taxonomy	tariquidar (IC50)	docetaxel anhydrous (IC50)
Kinesin-like protein KIF11	Homo sapiens (human)		0.0014
Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)		5.0119

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Balis, FM; Bates, SE; Chen, CC; Chen, X; Draper, D; Figg, WD; Fojo, T; Gardner, ER; Kelly, RJ; Piekarz, RL; Robey, RW; Steinberg, SM; Venkatesan, AM	1
Balis, FM; Chen, CC; Cole, D; Fox, E; Pastakia, D; Widemann, BC; Yang, SX	1

Trials

2 trial(s) available for tariquidar and docetaxel anhydrous

Article	Year
A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Feb-01, Volume: 17, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Docetaxel; Female; Humans; Lung Neoplasms; Middle Aged; Ovarian Neoplasms; Quinolines; Taxoids; Uterine Cervical Neoplasms	2011
Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors. Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:6 Topics: Adolescent; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; Child; Child, Preschool; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Male; Metabolic Clearance Rate; Neoplasms; Neutropenia; Quinolines; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting	2015

Article

Year

A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Feb-01, Volume: 17, Issue:3

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Docetaxel; Female; Humans; Lung Neoplasms; Middle Aged; Ovarian Neoplasms; Quinolines; Taxoids; Uterine Cervical Neoplasms

2011

Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors.

Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:6

Topics: Adolescent; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; Child; Child, Preschool; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Male; Metabolic Clearance Rate; Neoplasms; Neutropenia; Quinolines; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting

2015